AAN Annual Meeting Programs: P1 - Poster Session 1 | American Academy of Neurology®

P1 - Poster Session 1

Event Time:	Sunday May 5, 2019 11:30 am to 6:30 pm
Topic(s):	Research Methodology, Education, and History, Aging, Dementia, Cognitive, and Behavioral Neurology, Autoimmune Neurology, Cerebrovascular Disease and Interventional Neurology, Child Neurology and Developmental Neurology, Epilepsy/Clinical Neurophysiology (EEG), General Neurology, Headache, Movement Disorders, MS and CNS Inflammatory Disease, Neuro-oncology, Neuro-ophthalmology/Neuro-otology
Director(s):
Description:
Completion Message:
CME Credits:	0
Core Competencies:

Program Speakers - Tentative
Start/End Time	Title	Faculty
Currently there are no events in the timeline.

Disclosures
Speaker	Disclosure

Abstract Presenters
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	001	Development of Portable Pupillometer for Assessment of Neurological Disease	Disclosure: Dr. Moss has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with legal firms, Ology education, Springer, Medlink.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	001	Galcanezumab Significantly Reduced Health Care Resource Utilization and Acute Medication Use in Patients with Chronic Migraine: Findings from a Phase 3, Randomized, Double-Blind, Placebo-Controlled and Open-Label Extension	Disclosure: Dr. Joshi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Lilly, Teva, Supernus, Depomed, Promeus.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	001	Pathological Changes To the Visual System in Alzheimer’s Disease	Disclosure: Dr. Mistry has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	001	Cerebellar Atrophies in Neuromyelitis Optica Spectrum Disease (NMOSD) patients	Disclosure: Dr. Souza has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	001	A Stroke of Bad Luck : Breakthrough Ischaemic Strokes on DOAC Therapy	Disclosure: Dr. Chan has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	001	Investigating Directionality of Neurodegeneration in vivo in ALS using Multimodal MRI	Disclosure: Dr. Toh has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	001	Factors Contributing to Quality Of Life in Patients With Epilepsy.	Disclosure: Dr. Doyle has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	001	Tumors in the cauda equina: a SEER analysis of tumor types and predictors of outcome	Disclosure: Dr. Das has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	001	Optic Nerve Pathology and Visual Functioning in Pediatric Patients with anti-MOG Antibodies	Disclosure: Dr. Greenberg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis, Alexion, Celgene, and EMD Serono. Dr. Greenberg has received research support from CLENE Nanomedicine, Chugai, and Medimmune.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	001	Results from the Long-Term Open Label Extension Phase Analyses of BHV4157-201: A Phase IIb/III, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Troriluzole in Adult Subjects with Spinocerebellar Ataxia	Disclosure: Dr. Beiner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biohaven Pharmaceuticals. Dr. Beiner holds stock and/or stock options in Biohaven Pharmaceuticals which sponsored research in which Dr. Beiner was involved as an investigator. Dr. Beiner holds stock and/or stock options in Biohaven Pharmaceuticals.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	002	Macular Pigment In Multiple Sclerosis	Disclosure: Dr. Xhepa has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	002	Assessment of the Efficacy of Erenumab During the Open-Label Treatment (13–24 Weeks) of Subjects with Episodic Migraine Who Failed 2–4 Prior Preventive Treatments: Results of the LIBERTY Study	Disclosure: Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fee, speaking/teaching fee, from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals. Dr. Reuter has received research support from research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	002	iPSC Model of CHRFAM7A Effect on a7 Nicotinic Acetylcholine Receptor Function in the Human Context	Disclosure: Dr. Ihnatovych has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	002	Degree of Retinal Nerve Fiber Layer Thinning in Pediatric MOG-associated Optic Neuritis Appears Similar to Pediatric NMO	Disclosure: Dr. Shukla has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	002	Triglycerides, Creatinine and Body Mass Index are Independent Predictors of Occurrence of Stroke in Patients Adherent with Direct Oral Anticoagulant	Disclosure: Dr. Zhang has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	002	The Vitamin D Activator, CYP27B1, is a Novel Muscle Biomarker of ALS Disease Progression	Disclosure: Dr. Si has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	002	Characterizing Peri-Ictal Mood Changes in Patients with Epilepsy	Disclosure: Dr. Pahlavan has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	002	A Meta-Analysis Determining the Prevalence of Treatment-Associated Neurotoxicity in Cancer-Directed Immunotherapy with Antibodies	Disclosure: Dr. Horta has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	002	Neuronal Autoantibodies and Clinical Significance in Stiff-Person Spectrum Disorder	Disclosure: Dr. Kaneko has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	002	The impact of ethnicity on the phenotype of a monogenetic disorder: spinocerebellar ataxias type 3	Disclosure: Dr. Gan has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	003	Anti-glutamic acid decarboxylase associated neurologic disorders referred from Neuro-ophthalmology and Neurotology: A case series with characterization of vestibulo-ocular function	Disclosure: Dr. Wang has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	003	Patient Gains in Daily Functioning and Reductions in Disability with Galcanezumab among Patients with Episodic and Chronic Migraine	Disclosure: Dr. Ruff has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Ruff holds stock and/or stock options in Eli Lilly and Company.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	003	Neuroprotection of HP-beta-CD in the adult transgenic mice of Alzheimer disease	Disclosure: Dr. Yao has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	003	Systematic Review Investigating Relationship Between Neuromyelitis Optica Spectrum Disorder (NMOSD) and Vaccination	Disclosure: Dr. Vanood has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	003	Timing of Anti-Coagulation after Acute Ischemic Stroke and its relationship to risk of Intracranial Hemorrhage	Disclosure: Dr. Shehzad has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	003	Deconstructing progression of amyotrophic lateral sclerosis in stages: a Markov modeling approach.	Disclosure: Dr. Thakore has received research support from Novartis Pharmaceuticals Corporation.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	003	Cross-sensitivity of Psychiatric and Behavioral Side Effects with Antiepileptic Drug Use	Disclosure: Dr. Chen has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	003	MRI changes in patients with newly diagnosed glioblastoma treated as part of a Phase II trial with bavituximab, radiation, and temozolomide	Disclosure: Dr. Ly has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	003	Improving Patient Experience, Clinical Practice, and Provider Knowledge and Competence of Chronic Inflammatory Demyelinating Polyneuropathy with Online Continuing Medical Education	Disclosure: Dr. Roc has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	003	Comparative Profiling of Peripheral Blood Mononuclear Cells Proteome in Patients With Friedreich's Ataxia	Disclosure: Dr. Pathak has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	004	The Effects of Alcohol Consumption on Cognitive Performance Using the King-Devick Rapid Number Naming Test and the Mobile Universal Lexicon Evaluation System	Disclosure: Dr. Tejani has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	004	Impact of Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication	Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stephen D. Silberstein, MD, is a consultant and/or advisory panel member for and has received honoraria from Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva.. Dr. Silberstein has received research support from His employer receives research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare..
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	004	Inflammasome-derived cytokine IL18 suppresses amyloid-induced seizures in Alzheimer’s prone mice	Disclosure: Dr. Cheung has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	004	Neuromyelitis Optica Spectrum Disorders- Comparison as per Serostatus and Application of International Consensus Criteria	Disclosure: Dr. Bali has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	004	Treatment of floating thrombus with apixaban: report of a case.	Disclosure: Dr. Soto-Rincon has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	004	The anatomical substrate of bulbar impairment in ALS: insights from multiparametric brainstem imaging, corticobulbar connectivity and somatotopic motor cortex measures	Disclosure: Dr. Bede has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	004	Psychiatric Effects of Ketogenic Diet Therapies on Adults with Chronic Epilepsy	Disclosure: Dr. Shegelman has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	004	EEG Findings in Chimeric Antigen Receptor T-Cell (CAR-T) Related Encephalopathy Syndrome	Disclosure: Dr. Satyanarayan has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	004	Severe Cerebellar Syndrome Improved with Plasma Exchanges in Patient with Lung Adenocarcinoma Treated with Durvalumab	Disclosure: Dr. Tang has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	004	Overwhelming genetic heterogeneity and exhausting molecular diagnostic process in chronic and progressive ataxias: Facing up with an algorithm, a gene, a panel at the same time.	Disclosure: Dr. Zavala has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	005	Investigating the Structure and Function of the Retinohypothalamic Tract in Neuromyelitis Optica by Optical Coherence Tomography (OCT) and Pupillometry	Disclosure: Dr. Meltzer has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	005	Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients With Episodic Migraine: Results of a 1-Year Study	Disclosure: Dr. Brandes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Eli Lilly and Company, Depomed, Avanir Pharmaceuticals, Promius Pharma, and Supernus Pharmaceuticals. Dr. Brandes has received research support from Amgen, Eli Lilly and Company, CoLucid Pharmaceuticals, Teva Pharmaceuticals, Zosano, Allergan, and Biohaven Pharma.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	005	Procognitive and neuroprotective effect of 5-HT7 agonist in an animal model by ICV amyloid-b injection	Disclosure: Dr. Quintero Villegas has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	005	The Efficacy and Tolerability of Azathioprine for Patients with Neuromyelitis Optica Spectrum Disorder: A Systematic Review	Disclosure: Dr. Espiritu has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	005	Newer Anticoagulants in Patients with Atrial Fibrillation and Ischemic Stroke - a Two Year Experience	Disclosure: Dr. Bhattacharya has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	005	Neurophysiological Correlates of Excitability in ALS: Pretreatment Findings from the Retigabine and Mexiletine-2 Studies	Disclosure: Dr. Weiss has received research support from ALS Association and ALS Finding a Cure.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	005	Anxiety in Patients Admitted for Epilepsy Monitoring	Disclosure: Dr. Panda has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	005	Gliomatosis cerebri: Management and survival in the United States	Disclosure: Dr. Garcia has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	005	Progressive Neurodegeneration in X-Linked Agammaglobulinaemia	Disclosure: Dr. Gall has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	005	Preclinical Assessment of TAK-831, a Selective D-Amino Acid Oxidase Inhibitor, in a Genetic Model of Friedreich’s Ataxia (YG8sR)	Disclosure: Dr. Fradley has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	006	Angio-OCT micro vascular markers and central auditory disorder as indipendent predictors of cognitive impairment in the Great Age Study population	Disclosure: Dr. Sardone has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	006	The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients Who Previously Used Topiramate	Disclosure: Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals..
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	006	Structure and Pro-toxic Mechanism of the Human Hsp90/PPIase/Tau Complex	Disclosure: Dr. Oroz has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	006	Autonomic Dysfunction in People with Neuromyelitis Optica Spectrum Disorders	Disclosure: Dr. Crnosija has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	006	Aspirin Resistance And Ischemic Stroke: A Prospective Study In Indian Population.	Disclosure: Dr. Sisodia has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	006	Neuroelectric Biomarkers of Network Dysfunction in Amyotrophic Lateral Sclerosis	Disclosure: Dr. Nasseroleslami has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	006	A severe bone loss in pharmacoresistant epilepsy associates with enzyme-inducing antiepileptic drug	Disclosure: Dr. Rigotti has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	006	Incidence of Distant Recurrence in Adult Gliomas	Disclosure: Dr. Pan has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	006	Safety of Checkpoint Inhibitors for Cancer Treatment in Patients with Multiple Sclerosis: A Case Report	Disclosure: Dr. Isitan has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	006	Ultrastructural Changes in Brain Stem Pathways in a Patient with Ataxia Associated with SPG7 Mutations	Disclosure: Dr. Ringman has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with InnoSense, LLC, RENEW. Dr. Ringman has received research support from Avid Pharmaceuticals.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	007	Non-chiasmal bitemporal pseudo-hemianopia: case series	Disclosure: Dr. Bingeliene has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	007	Randomized, Double-Blind, Pilot Study Comparing 3 Mg Subcutaneous Sumatriptan With 6 Mg Subcutaneous Sumatriptan Using DFN-11 Autoinjector for the Acute Treatment Of Rapidly-Escalating Migraine Attacks	Disclosure: Dr. Cady has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Full time employee at Alder BioPharmaceuticals, Inc..
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	007	Reciprocal regulation of filamin A and amyloid precursor protein expression in astrocytes	Disclosure: Dr. Ekuta has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	007	The Effect of Pain on Quality of Life and Co-occurring Symptoms in Patients with Neuromyelitis Optica Spectrum Disorder	Disclosure: Dr. Mealy has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Viela Bio.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	007	Smoking and Clopidogrel resistance in ischemic stroke	Disclosure: Dr. Kang has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	007	Do Sleep Scales Correlate with Pulmonary Function in ALS? Results From the ALS Nutrition/NIPPV Study Group	Disclosure: Dr. Khazaal has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	007	Anxiety and Depression Symptoms in the Epilepsy Clinic: Examining Psychiatric Treatment Characteristics in a Learning Health System Model	Disclosure: Dr. Jones has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	007	CAR-T-cell-Related Encephalopathy Syndrome: High Rates of Neurotoxicity in Clinical Practice	Disclosure: Dr. Yuen has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	007	Progressive Parkinsonism and Cognitive Changes: A Rare Presentation of Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS)	Disclosure: Dr. Khayatkhoei has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	007	Updates to the National Institute of Neurological Disorders and Stroke (NINDS) Friedreich’s Ataxia (FA) Common Data Element (CDE) Recommendations: 2018 FA Working Group Review	Disclosure: Dr. Gay has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	008	Prognostic Factors of Poor Outcome in Idiopathic Intracranial Hypertension	Disclosure: Dr. Farhat has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	008	Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine With Concomitant Preventive Medication Use	Disclosure: Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	008	Impaired Brain Cells Response in Obesity	Disclosure: Dr. Latif has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	008	Development of Resistance to B-Cell Depletion Following Ten Years of Effective Rituximab Treatment in a Patient with Neuromyelitis Optica	Disclosure: Dr. Harel has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	008	The Effect of New P2Y12 Receptor Antagonist, Ticagrelor, On Platelet Reactivity in Patients With Clopidogrel Resistance Undergoing Neuroendovascular Procedures.	Disclosure: Dr. Jahngir has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	008	Validation of the revised classification of cognitive and behavioral impairment in ALS	Disclosure: Dr. Vasta has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	008	A survey of neurologists screening and management of depression in patients with epilepsy	Disclosure: Dr. Riotto has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	008	A case series of metastatic glioblastoma at Memorial Sloan Kettering Cancer Center	Disclosure: Dr. Noch has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	008	The potential of Teriflunomide for regional and global brain volume protection in single subject MS patients	Disclosure: Dr. Raji has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Serono, Genzyme, Novartis. Dr. Raji has received research support from Genzyme.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	008	Frataxin deficiency causes excessive mitochondrial fragmentation associated with mitochondrial fission core components	Disclosure: Dr. Johnson has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	009	The standard swinging flashlight test: reliable or not	Disclosure: Dr. Boucher has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	009	Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine	Disclosure: Dr. Krege has received compensation for employment at Eli Lilly and Company Dr. Krege holds stock and/or stock options in Eli Lilly.
Aging and Dementia: Animal and Cell Models
Start Time	Pub.	Title	Presenter
11:30 AM	009	Novel Insights into Intersectin1 Mechanistic Contributions to Brain Disorders	Jessica Wilson Disclosure: Dr. Wilson has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	009	A Case of Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy(GFAP) Meningoencephalomyelitis Responsive to Infliximab	Disclosure: Dr. Rodriguez has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	009	Retrospective Comparison of Medication Therapy Management and Stroke/TIA Outcomes in Patients Who Have Undergone Testing for Antiplatelet Responsiveness and Pharmacist Intervention and versus Those Who Have Not	Disclosure: Dr. Westphal has received research support from ASHP, Acadia, Dent Family Foundation.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	009	Genetic Testing Has a High Diagnostic Yield for Individuals with ALS regardless of Family History	Disclosure: Dr. Yang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with GeneDx.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	009	Symptoms and Impacts in Epilepsy: Findings from Qualitative Patient Interviews	Disclosure: Dr French did not receive personal income, but received NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Addex, Aeonian, Alexza, Anavex, Axcella Health, Axovant, Biogen, Biomotiv/Koutif, Blackfynn, Bloom Science, Bridge Valley Ventures, Cavion, Cerebral Therapeutics, Cerevel, Clinilabs, Concert Pharmaceuticals, Covance, Crossject, CuroNZ, Eisai, Empatica, Engage Therapeutics, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, MonosolRx, Neurelis, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Pfizer, Pfizer-Neusentis, Praxis, Redpin, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Ultragenyx, Upsher Smith, Vyera, West Therapeutic Development, Xenon, Xeris, Zogenix, Zynerba. Dr. French has received research support from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. .
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	009	Primary brain tumors admitted to the neurological intensive care unit: a single institution observational study	Disclosure: Dr. Kang has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	009	Acute disseminated encephalomyelitis following Mycoplasma pneumoniae infection in a young adult collegiate athlete	Disclosure: Dr. Kyrtsos has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	009	Structural Magnetic Resonance Imaging Correlates of Neurodegeneration in a Spinocerebellar Ataxia Type 7 Cohort	Disclosure: Dr. Parker has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	010	Acute Optic Neuritis: looking for an accurate and early assessment	Disclosure: Dr. Fernandez has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	010	Evaluation of Cardiovascular Risks in Adult Patients with Episodic or Chronic Migraine Treated With Galcanezumab: Data From Three Phase 3, Randomized, Double-Blind, Placebo-Controlled Studies	Disclosure: Employment: Eli Lilly and Company Employee and minor stockholder of Eli Lilly and Company
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	010	Age of onset in genetic prion disease and the design of preventive clinical trials	Disclosure: Dr. Minikel has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	010	Neuromyelitis Optica Spectrum Disorder in a Tertiary Hospital in the Philippines: A Case Series	Disclosure: Dr. Espiritu has nothing to disclose.
Antithrombotic Treatment in Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	010	Fourteen-day Delay of Cerebral Ischemia due to Vasospasm after Traumatic Subarachnoid Hemorrhage in Mild Head Injury	Disclosure: Dr. Maran has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	010	The Canadian ALS Neuroimaging Consortium (CALSNIC)	Disclosure: Dr. Kalra has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	010	Impact of Autism Spectrum Disorder Diagnosis on Epilepsy in Patients with Tuberous Sclerosis Complex	Disclosure: Dr. Drogin has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	010	Patterns of Death and Palliative Care in Glioma Patients	Disclosure: Dr. Barbaro has nothing to disclose.
Autoimmune Neurology/MS and CNS Inflammatory Disease ePoster Session
Start Time	Pub.	Title	Presenter
11:30 AM	010	Acute and Lasting Benefits of a Virtual Reality in Multiple Sclerosis	Disclosure: Dr. Shaw has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	010	Inpatient Verses Outpatient Workup of Patients with Ataxia and Suspected Paraneoplastic Cerebellar Degeneration: Does Workup Location Matter?	Disclosure: Dr. Witek has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	011	Transcriptional control of optic nerve injury associated retinal ganglion cell death	Disclosure: Dr. Syc has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	011	Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication	Disclosure: Dr. McAllister has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen Inc., Teva Neuroscience, Alder, Promius, Electrocore, and Allergen, Inc. Dr. McAllister has received personal compensation in an editorial capacity for Practical Neurology. Dr. McAllister has received research support from Alder, Amgen Inc., Teva Neuroscience, Sunovion, San-bio, Biohaven, Allergan, Inc., Novartis, ATI, Roche Diagnostics Corporation, Esai Inc., and Biogen Idec.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	011	Tau and neurodegeneration mismatch is a signature of polypathology in AD continuum	Disclosure: Dr. Wolk has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Neuronix. Dr. Wolk has received research support from Avid/Lilly, Biogen, and Merck.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	011	Area Postrema syndrome: A Short Case Series Highlighting Diagnostic dilemmas, Clinical features and Outcome	Disclosure: Dr. Nadig has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	011	The Role of Intravenous Thrombolysis in the Prediction of Functional Outcome in Patients who undergo Endovascular Thrombolysis with Newer Generation Stent Retrievers	Disclosure: Dr. aijb has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	011	Relationship between Forced Vital Capacity and Slow Vital Capacity in individuals with Amyotrophic Lateral Sclerosis Patients	Disclosure: Dr. Reynolds has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	011	Employment and socioeconomic status after epilepsy surgery: A study in a Mexican cohort.	Disclosure: Dr. Jorge De Sarachaga has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	011	Psychiatric Disturbance As a Presenting Symptom in Central Nervous System Lymphoma	Disclosure: Dr. Sharma has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	011	Cerebellar endoplasmic reticulum-mitochondria calcium signal pathways are impaired in the KIKO mouse model of Friedreich ataxia	Disclosure: Dr. Lin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Impel NeuroPharma. Dr. Lin has received research support from Impel NeuroPharma.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	012	Dwarf gecko as a model for studying retinal neurogenesis	Disclosure: Dr. Mendez has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	012	The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Chronic Migraine Patients With Concomitant Preventive Medication Use	Disclosure: Dr. Gandhi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Teva Pharmaceuticals..
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	012	Interactions Between Brain Structures and Genetic Variants in Neurotransmitter Systems as Potential Biomarkers for Hallucinations and Delusions in Alzheimer’s Disease	Disclosure: Dr. Ahmed has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	012	An Atypical NMO Presentation with Locked-In Syndrome	Disclosure: Dr. Rehman has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	012	Does Use of Adjunctive Therapy to Mechanical Thrombectomy Improve Outcomes Without Significant Risk in LVOs.	Disclosure: Dr. Singh has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	012	MRI Alterations in the Brachial Plexus of ALS Patients	Disclosure: Dr. Scamarcia has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	012	Quality Of Life And Disease Progress In Patients With Drug Resistant Epilepsy	Disclosure: Dr. Olivas has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	012	Characterization of Seizures (ILAE 1981 and 2017 Classifications) and their Response to Treatment in a Cohort of Patients with Glial Tumors.	Disclosure: Dr. Casas-Parera has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	012	Ataxia with Transglutaminase 6 Mutation (SCA35) Responding to Gluten-Free Diet: A Case Report	Disclosure: Dr. Lin has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	013	Inferior colliculus neurons that express the neuropeptide VIP project to auditory nuclei in the brainstem and thalamus.	Disclosure: Mr. Edelbrock has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	013	Improvement in Response Over Time With Fremanezumab in Patients Who Reverted From a Chronic to an Episodic Migraine Classification	Disclosure: Dr. Halker has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Biohaven, and Allergan. Dr. Halker has received personal compensation in an editorial capacity for Current Neurology & Neuroscience Reports.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	013	Longitudinal Decline in Lexical Retrieval is Related to AD Pathologic Burden in Middle Frontal, Superior and Temporal Regions in Progressive Aphasia	Disclosure: Dr. Bove has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	013	Clinical characteristics, diagnostic and outcome differences in patients with optic neuritis	Disclosure: Dr. Siegel has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	013	Prior Intravenous Thrombolytics Administration is Associated with Increased Hospital Bills & Intracranial Hemorrhage Rates Without Improved Outcomes in Mechanical Thrombectomy Patients	Disclosure: Dr. Hassan has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	013	Intrathecal delivery of ALS cerebrospinal fluid induces motor deficits and motor neuron death in mice	Disclosure: Dr. Wong has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	013	Factors Associated with Quality of Life in a Low-income Population with Epilepsy.	Disclosure: Dr. Espinosa Jovel has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	013	Prognostic Factors and Survival in Primary CNS Lymphoma Patients at Yale	Disclosure: Dr. Prado has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	013	Diagnostic Value of Next Generation Sequencing Ataxia Panel as a Part of Multistep Investigation Approach in Sporadic and Autosomal Recessive Cerebellar Ataxias in Russia	Disclosure: Dr. Seliverstov has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	014	Delayed Development of a Dural AV Fistula and PTEN Hamartoma Syndrome in Pseudo-Idiopathic Intracranial Hypertension	Disclosure: Dr. Gold has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	014	Single and Multiple Doses of Ubrogepant Are Not Associated With a Clinically Significant Elevation of Alanine Aminotransferase in Healthy Adult Males	Disclosure: Dr. Bondiskey has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck Sharp & Dohme Corp. Dr. Bondiskey holds stock and/or stock options in Merck Sharp & Dohme Corp., which sponsored research in which Dr. Bondiskey was involved as an investigator.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	014	Hippocampal tau pathology burden in Lewy body disorders	Disclosure: Dr. Ittyerah has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	014	Spectral-Domain Optical Coherence Tomography in Autoimmune Disorders with Optic Neuropathy: A Retrospective Analysis of Distinctive Features.	Disclosure: Dr. Sriwastava has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	014	Outcome of mechanical thrombectomy in patients with acute ischemic stroke on anticoagulation therapy	Disclosure: Dr. Karim has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	014	Radicava® (edaravone) for Amyotrophic Lateral Sclerosis: New Formulation and Its Development Plan	Disclosure: Dr. Takei has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma Corporation, Inc.. Dr. Takei holds stock and/or stock options in Mitsubishi Tanabe Pharma Corporation, Inc. which sponsored research in which Dr. Takei was involved as an investigator. .
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	014	Effect of Seizure Auras on Mood in Epilepsy: the ESAME Survey	Disclosure: Dr. Bumsch has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	014	Feasibility of a Structured Tumor-related Epilepsy Education Intervention in Adult Gliomas	Disclosure: Dr. Wasilewski has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	014	Autosomal Recessive Spastic Ataxia of Charlovoix-Saguenay. A new pathogenic mutation.	Disclosure: Dr. Flanigan has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	015	Vancomycin Ototoxicity May Lead to Bilateral Vestibular Hypofunction	Disclosure: Dr. Zak has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	015	Long-Term Safety of Fremanezumab: Results of a 1-Year Study	Disclosure: Dr. Ning has nothing to disclose.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	015	Neuropathological findings in Parkinson’s disease with mild cognitive impairment	Disclosure: Dr. Knox has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	015	Utilizing T-Cell Suppression In Recurrent GFAP Antibody Encephalitis	Disclosure: Dr. Nicholson has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	015	Monitored anesthesia care by sedation-trained providers in acute stroke thrombectomy.	Disclosure: Dr. Slawski has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	015	BRIDGE: Dynamic Imagery and Art Therapy in ALS- A Clinical Study to Improve Patient Expression and Wellness	Disclosure: Dr. King has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	015	Self-Reported Depression and Anxiety Scores Similar in Patients with Temporal and Extra-Temporal Lobe Epilepsy	Disclosure: Dr. Abe has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	015	Primary CNS posttransplant lymphoproliferative disease (PCNS-PTLD): Diagnosis, minimal treatment toxicity, and surveillance in renal transplant patients	Disclosure: Dr. Summers has nothing to disclose.
Ataxia
Start Time	Pub.	Title	Presenter
11:30 AM	015	Opsoclonus Myoclonus Ataxia Related to West Nile Virus	Disclosure: Dr. Boucekkine has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	016	Observation of Angular Deformity of a Straight Line	Disclosure: Dr. Tishman has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	016	Assessment of the Long-Term Safety and Efficacy of Erenumab During Open-Label Treatment of Patients With Chronic Migraine	Disclosure: Dr. Tepper has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Acorda, Alder, Alexsa, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Pharmaceuticals Canada, Axsome Therapeutics, BioDelivery Sciences International, Biohaven, Charleston Labs, Decision Resources, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK, Guidepoint Global, Impel, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Nordic BioTech, Novartis, Pfizer, Reckner Healthcare, Relevale, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Teva, Theranica, Thought Leader Select, Trinity Partners, XOC, and Zosano. Dr. Tepper has received personal compensation in an editorial capacity for American Headache Society. Dr. Tepper has received research support from Alder, Allergan, Amgen, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Neurolief, Novartis, Teva, and Zosano.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	016	RS4548513 (CTNNA3): A Genetic Risk Factor for Visual Construction Deficiency in Parkinson's disease	Disclosure: Dr. Murezzan has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	016	A Case of an Aggressive Demyelinating NMO Spectrum Disorder-like Event in a Rheumatoid Arthritis Patient Treated with Tofacitinib	Disclosure: Dr. Eckert has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	016	General Anesthesia for Thrombectomy in Ischemic Stroke Leads to Poor Outcomes as Compared to Conscious Sedation	Disclosure: Dr. Bhan has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	016	Predicting benign brachial monomelic amyotrophy: factors at presentation that differentiate from amyotrophic lateral sclerosis	Disclosure: Dr. Mistry has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	016	Seizure-induced demargination predicts peri-ictal respiratory decompensation	Disclosure: Dr. Vega has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	016	Telehealth for Specialty Neurofibromatosis (NF) Care	Disclosure: Dr. Jordan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Recursion Pharmaceuticals, NF Network, and Elsevier Publishing.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	016	Results of an Open Label, Dose Escalating, Phase 1 Clinical Trial Evaluating the Safety of a Human Neural Stem Cell Based Therapy in Parkinson’s Disease	Disclosure: Dr. Kern has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with International Stem Cell Corporation. Dr. Kern has received compensation for serving on the Board of Directors of International Stem Cell Corporation. Dr. Kern holds stock and/or stock options in International Stem Cell Corporation which sponsored research in which Dr. Kern was involved as an investigator. . Dr. Kern holds stock and/or stock options in International Stem Cell Corporation. Dr. Kern has received research support from International Stem Cell Corporation.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	017	Herpes Simplex Virus (HSV)-2 Meningoencephalitis-associated Bilateral Optic Neuritis Successfully Treated with Steroids and Intravenous Immunoglobulin	Disclosure: Dr. El Ammar has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	017	Immunogenicity Assessment from Phase 3 Galcanezumab Trials in Patients with Episodic or Chronic Migraine	Disclosure: I am full-time employee and a stock shareholder of Eli Lilly and Company.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	017	Genetic Polymorphisms Associate with Frontotemporal Cortical Thickness in Sporadic Amyotrophic Lateral Sclerosis	Disclosure: Dr. Placek has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	017	Anti-APQ4-negative NMO Spectrum Disorders with and without anti-MOG: A Retrospective Case Series	Disclosure: Dr. Mirzoev has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	017	The first objective predictor of the hemorrhagic events after endovascular treatment of acute ischemic stroke using 2D parametric parenchymal blood flow	Disclosure: Dr. Elsaid has nothing to disclose.
Epilepsy: Comorbidities and SUDEP
Start Time	Pub.	Title	Presenter
11:30 AM	017	Quantitative Pupil Measurements In Epileptic Seizures And Non-Epileptic Events – A Step Towards SUDEP Pathophysiologic Mechanisms.	Disclosure: Dr. Yerram has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	017	Pineal parenchymal tumors of intermediate differentiation treated with ventricular radiation and temozolomide	Disclosure: Dr. Low has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	017	PD-1102: A Phase 1 study of VY-AADC01 Administered Using a Posterior Approach in Patients with Parkinson’s Disease and Motor Fluctuations	Disclosure: Dr. Van Laar has received research support from Biogen.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	018	A Chronic Progressive Optic Neuropathy in a Patient with Anti-Myelin-Oligodendrocyte Glycoprotein (MOG) Antibodies	Disclosure: Dr. Gold has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	018	Absence of Clinically Significant Drug Interactions With Coadministration of Ubrogepant and an Ethinyl Estradiol/Norgestimate Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis	Disclosure: Dr. Li has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co, Inc.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	018	Exome sequencing in carriers of the C9orf72 repeat mutation to identify pathogenic variants in other neurodegenerative genes	Disclosure: Dr. Tran has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	018	Paraneoplastic Neuromyelitis Optica Spectrum Disorder in a Patient with Endometrial Adenocarcinoma	Disclosure: Dr. Granger has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	018	The Processing Time for Recanalization and Size of Ischemic Lesions on DWI Is Related with Complete Reperfusion After Mechanical Thrombectomy	Disclosure: Dr. Shin has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	018	An Update of Study of ALS Reversals: LifeTime Exposures (StARLiTE)	Disclosure: Dr. Crayle has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	018	Utilizing Optical Coherence Tomography to Assess the Effect of Phenytoin on Retinal Structures in Epilepsy Patients	Disclosure: Dr. Gilroy has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	018	A Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma	Disclosure: Dr. Rogers has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	018	“Dual Frequency” Deep Brain Stimulation Programming Paradigm for Gait and Balance Impairment in Parkinson’s Disease	Disclosure: Dr. Karl has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	019	Saturday Night Retinopathy – A Rare Case of Acute Onset Vision Loss and Ophthalmoplegia	Disclosure: Dr. Dorotan has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	019	Absence of Clinically Significant Drug Interactions With Coadministration of Atogepant and an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Subjects: A Phase 1 Pharmacokinetic Analysis	Disclosure: Dr. Ankrom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck & Co, Inc.. Dr. Ankrom holds stock and/or stock options in Merck & Co, Inc., which sponsored research in which Dr. Ankrom was involved as an investigator.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	019	TDP-43 cytoplasmic inclusion formation in C9orf72-associated FTLD/ALS	Disclosure: Dr. Lee has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	019	The Essence and Boundaries of anti-Myelin Oligodendrocyte Glycoprotein Syndromes	Disclosure: Dr. Liu has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	019	Inter-facility transfer workflow for thrombectomy in a rural stroke network: Longer Door-In-Door-Out (DIDO) time delays thrombectomy	Disclosure: Dr. Abdelhak has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	019	Health utility declines with advancing Fine'til 9 stage of ALS	Disclosure: Dr. Thakore has received research support from Novartis Pharmaceuticals Corporation.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	019	Safety of Cenobamate (YKP3089) as Adjunctive Treatment for Uncontrolled Focal Seizures in a Large, Multicenter, Open-Label Study	Disclosure: Yes: all funds paid to Thomas Jefferson University with research support from Medtronic, SK Life Science, Takeda, UCB Pharma, Neurelis, Eisai, Engage, Cavion
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	019	Impact of Delay of Chemoradiation (CRT) in Newly Diagnosed Glioblastoma (GBM) Treated With Stupp Protocol	Disclosure: Dr. Ali has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	019	National Trends in Utilization of Deep Brain Stimulation In Primary Movement Disorders: National Inpatient Sample Study 2006-2014	Disclosure: Dr. Vellipuram has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	020	A Case of Heidenhain Variant Creutzfeldt-Jakob Disease Presenting with Isolated Homonymous Quadrantanopia and Corresponding Nuclear Imaging Findings	Disclosure: Dr. Bhadola has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	020	Long-term Efficacy of Erenumab in Patients With Episodic Migraine Who Have Failed Prior Preventive Migraine Therapies	Disclosure: Dr. Reuter has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with consulting fee, speaking/teaching fee, from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals. Dr. Reuter has received research support from research grants from Allergan, Amgen, Autonomic Technologies, CoLucid, ElectroCore, EliLilly, Medscape, Novartis, StreamMedUp, TEVA Pharmaceuticals.
Aging and Dementia: Genetics and Neuropathology
Start Time	Pub.	Title	Presenter
11:30 AM	020	Small Vessel Characteristics of Autopsied Patients with CADASIL and Those Heterozygous for HTRA1 Mutations: 3D Analysis Using the CUBIC Tissue Clearing Technique	Disclosure: Dr. Saito has nothing to disclose.
Autoimmune (AQP4/MOG) Gliopathies and NMOSDs
Start Time	Pub.	Title	Presenter
11:30 AM	020	A Phase 1/2a Open-Label Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) into Subjects with Transverse Myelitis (TM)	Disclosure: Ms. Cameron Watts has received research support from Myeletis Organization.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	020	RAPIDTM Based Treatment Algorithms Lead to Faster Activation of Neurointervention Team and Reduce Recanalization Times	Disclosure: Dr. Mehta has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	020	Biomarker Supervised G-CSF (Filgrastim) Response in ALS Patients	Disclosure: Dr. Johannesen has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	020	Analysis of Psychiatric Adverse Events and Suicidality in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures	Disclosure: Dr. Salpekar has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion Pharmaceuticals Inc. (consulting only). Dr. Salpekar has received research support from Lundbeck (institution only).
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	020	Neurological Adverse Effects Due to Programmed Death (PD-1) Inhibitors	Disclosure: Dr. Shi has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	020	Correlation of Electrode Location and Outcomes of Gait and Axial Function in Parkinson’s Disease Patients managed with Subthalamic Deep Brain Stimulation	Disclosure: Dr. Huang has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	021	Posterior Ischemic Optic Neuropathy, a previously unknown complication of lung transplantation	Disclosure: Dr. Keller has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	021	The Use of Standing Desks to Address Self-Regulating Behavior in Elementary Students	Disclosure: Dr. Wachob has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	021	Long-term Safety and Efficacy of Lasmiditan for Acute Treatment of Migraine Over a One-Year Period: Interim Results of an Open-Label Phase 3 Study (GLADIATOR)	Disclosure: Dr. Brandes has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Amgen, Eli Lilly and Company, Depomed, Avanir Pharmaceuticals, Promius Pharma, and Supernus Pharmaceuticals. Dr. Brandes has received research support from Amgen, Eli Lilly and Company, CoLucid Pharmaceuticals, Teva Pharmaceuticals, Zosano, Allergan, and Biohaven Pharma.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	021	The Structural Basis of Susac's Syndrome	Disclosure: Dr. Munoz has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cortexyme.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	021	To Stay or To Go? Utilization of a Mobile Interventional Stroke Team Shortens Time to Treatment in Large Vessel Occlusion	Disclosure: Dr. Velickovic Ostojic has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	021	Increasing the Efficiency of ALS Clinical Trials Using Machine Learning	Disclosure: Dr. Ennist has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Origent Data Sciences.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	021	Safety and Efficacy of Adjunctive Perampanel in Younger (aged 4 to <7 years) and Older (7 to <12 years) Pediatric Patients with Partial-Onset Seizures (POS) or Primary Generalized Tonic-Clonic Seizures (PGTCS): Final Results from the 311 Core Study	Disclosure: Dr. Fogarasi has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with UCB and Novartis.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	021	The Financial Burden of Central Nervous System Cancers in the United States	Disclosure: Dr. Pena has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	021	The Use of Omni vs. Directional Programming in Parkinson Disease and Essential Tremor DBS Patients	Disclosure: Dr. Sharma has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	022	Wernicke Encephalopathy Mimicking Idiopathic Intracranial Hypertension	Disclosure: Dr. Leon has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	022	Model-Based Truncation of Cognitive Test Batteries to Minimize Assessment Time and Information Loss	Disclosure: Dr. Vermeent has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Philips.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	022	Long-Term Impact of Fremanezumab on Headache-Related Disability and Quality of Life in Patients Who Reverted From a Chronic to an Episodic Migraine Classification	Disclosure: Dr. Ailani has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder, Amgen, Allergan. Eli Lilly and Company,Teva, Impel, Satsuma, Miller Communications, Avent, Revance, Biohaven, Zosano. Dr. Ailani has received personal compensation in an editorial capacity for Current Pain and Headache Reports Section Editor. Dr. Ailani has received research support from American Migraine Foundation, Biohaven, Allergan, Eli Lilly and Co, Zosano.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	022	Progressive Brain Atrophy and Leptomeningeal Enhancement in Susac Syndrome	Disclosure: Dr. Malik has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	022	Initial symptoms and delay in treatment of patients with posterior circulation strokes undergoing endovascular therapy	Disclosure: Dr. Gomez has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	022	How the National Amyotrophic Lateral Sclerosis (ALS) Registry Can Help with Your Research	Disclosure: Dr. Kaye has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with McKing Consulting Corp.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	022	Analysis of Allergic Reactions in Clinical Trials of Eslicarbazepine Acetate in Children (Aged 4–17 Years) with Focal Seizures	Disclosure: Dr. Resnick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eisai, Sunovion Pharmaceuticals Inc., Supernus, Mallinckrodt.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	022	Facial palsy induced by cancer immunotherapy: a single center retrospective study	Disclosure: Dr. Yuen has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	022	APOE E4 Carrier Status Modulates Cognitive Outcome after Deep Brain Stimulation in Parkinson’s Disease Patients	Disclosure: Dr. Yoon has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	023	Acute Bilateral Ophthalmoparesis due to Bacterial Meningitis in the Setting of Sphenoid Sinusitis	Disclosure: Dr. Pereira has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	023	Impact of Educational Inequality on the Incidence of Post-stroke Vascular Mild Cognitive Impairment - Application of the Previous Study on Stratified Education-adjusted MoCA Assessment	Disclosure: Dr. Pisanuwongrak has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	023	Eptinezumab Reduces Migraine Frequency Within the First Month After Treatment in Patients with Episodic or Chronic Migraine	Disclosure: Dr. Winner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Allergan, Amgen, Supernus, Teva, Novartis, Avanir, and Promius.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	023	Pachymeningitis in Rheumatic Disease	Disclosure: Dr. Kneeland has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	023	Posterior Circulation Large Vessel Occlusions are Associated with Longer Door-?to-Groin Time	Disclosure: Dr. Almallouhi has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	023	Characteristics of respiratory dysfunction in amyotrophic lateral sclerosis: a retrospective cohort study in 236 cases	Disclosure: Dr. Fu has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	023	A Two-Part, Double-Blind, Placebo-Controlled, Inpatient, Dose-Ranging Efficacy Study of Staccato Alprazolam (STAP-001) in Patients with Epilepsy with a Predictable Seizure Pattern: Results from the Initial Open-Label Feasibility Part	Disclosure: Dr French did not receive personal income, but received NYU salary support from the Epilepsy Foundation and for consulting work and/or attending Scientific Advisory Boards on behalf of the Epilepsy Study Consortium for Acadia, Adamas, Addex, Aeonian, Alexza, Anavex, Axcella Health, Axovant, Biogen, Biomotiv/Koutif, Blackfynn, Bloom Science, Bridge Valley Ventures, Cavion, Cerebral Therapeutics, Cerevel, Clinilabs, Concert Pharmaceuticals, Covance, Crossject, CuroNZ, Eisai, Empatica, Engage Therapeutics, Epitel, GW Pharma, Idorsia, Impax, Ionis, J&J Pharmaceuticals, Marinus, MonosolRx, Neurelis, Novartis, Otsuka Pharmaceutical Development, Ovid Therapeutics Inc., Pfizer, Pfizer-Neusentis, Praxis, Redpin, Sage, Sancillio, Shire, SK Life Sciences, Springworks, Stoke, Sunovion, Supernus, Takeda, UCB Inc., Ultragenyx, Upsher Smith, Vyera, West Therapeutic Development, Xenon, Xeris, Zogenix, Zynerba. Dr. French has received research support from Biogen, Cavion, Eisai, Engage, GW Pharma, Lundbeck, Neurelis, Ovid, SK Life Sciences, Sunovion, UCB, and Zogenix as well as grants from the Epilepsy Research Foundation, Epilepsy Study Consortium, and NINDS. .
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	023	Planning a Glioma Partial Resection with DTI Tractography and Virtual Reality	Disclosure: Dr. Sanicola has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	023	Using a quality improvement framework to examine deep brain stimulation in Parkinson’s disease: the RAD-PD initiative	Disclosure: Dr. Jimenez Shahed has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with St. Jude Medical/Abbott, Medtronic, Boston Scientific, Teva, Bracket,Nuvelution, Sunovion,. Dr. Jimenez Shahed has received research support from Medtronic, St. Jude Medical/Abbott, Lily, Wilsons Therapeutics, Sunovion, Nuvelution.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	024	Optic Neuritis and Intracranial Hypertension Caused by Chronic Lymphocytic Leukemia, Case Report	Disclosure: Dr. Madani has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	024	Using the Montreal Cognitive Assessment (MoCA): to Predict Three Month Recovery Following a Stroke	Disclosure: Dr. Julayanont has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	024	Long-Term Efficacy of Fremanezumab in Patients With Chronic Migraine and Comorbid Moderate to Severe Depression	Disclosure: Dr. Lipton has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with American Academy of Neurology, Alder, Allergan, American Headache Society, Amgen, Autonomic Technologies, Avanir, Biohaven, Biovision, Boston Scientific, Dr. Reddy’s, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Pernix, Pfizer, Supernus, Teva, Trigemina, Vector, and Vedanta. Dr. Lipton has received compensation for serving on the Board of Directors of eNeura and Biohaven. Dr. Lipton holds stock and/or stock options in Biohaven, which sponsored research in which Dr. Lipton was involved as an investigator. Dr. Lipton holds stock and/or stock options in Biohaven. Dr. Lipton has received research support from Migraine Research Foundation, the National Headache Foundation, and Amgen.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	024	Clinical spectrum of patients with Primary central nervous system vasculitis	Disclosure: Dr. Dash has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	024	First Pass Rates Differ Between Anterior Circulation And Vertebrobasilar Occlusions During Mechanical Thrombectomy For Emergent Large Vessel Occlusions	Disclosure: Dr. Daniel has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	024	McGill University Single Item Quality-of-Life ( QoL ) Scale Compared with ALS Health-Related Quality-of-Life Likert Scales Including Breathing QoL Measurement	Disclosure: Dr. Brooks has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Mitsubishi Tanabe Pharma USA, Biohaven, Cytokinetics, ITF Pharma. Dr. Brooks has received personal compensation in an editorial capacity for American Journal of Managed Care. Dr. Brooks has received research support from Medicinova, Neuraltus, Cytokinetics,Santhera, Biogen, ITF Pharma, Acceleron, Center for Disease Control, Orion, Biohaven.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	024	A Post-Marketing Observational Study to Evaluate the Safety and Tolerability of Perampanel as Add-On Therapy in Patients with Epilepsy Aged =12 Years	Disclosure: Dr. Maguire has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	024	iPROMPT: Integrated Predictive Radiographic biOMarkers of Progressed high grade astrocytic Tumors	Disclosure: Dr. Gatson has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novocure (Optune).
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	024	CLOVER-DBS: A Prospective, Multicenter Clinical Study with Blinding to Evaluate a Closed Loop Programming Algorithm for Directional Leads Based on External Feedback	Disclosure: Dr. Wenzel has nothing to disclose.
Neuro-Ophthalmology/Neuro-Otology
Start Time	Pub.	Title	Presenter
11:30 AM	025	Binasal Visual Field Defects in a Child with Acute Necrotizing Encephalopathy	Disclosure: Dr. Liu has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	025	Concordance Between Structural and Functional Connectivity Reflects Available Cognitive Reserve in Multiple Sclerosis During Cognitive Rehabilitation	Disclosure: Dr. Fuchs has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	025	Early Impact of Eptinezumab on the Health-Related Quality of Life (HRQoL) of Patients with Episodic or Chronic Migraine: SF-36 Analysis Across the Spectrum of Migraine	Disclosure: Dr. Diamond has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alder BioPharmaceuticals, Amgen Inc., Avanir Pharmaceuticals, Depomed Inc., Eli Lilly and Co., Promius Pharma, Supernus Pharmaceuticals, Teva Pharmaceuticals, and Upsher-Smith Laboratories.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	025	Case of hypertrophic pachymeningitis with positive MPO-ANCA antibodies	Disclosure: Dr. Castrodad- Molina has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	025	No Association Between Number of Stent Retriever Passes and Hemorrhagic Transformation for Mechanical Thrombectomy Patients.	Disclosure: Dr. Hassan has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	025	Safety and Efficacy of Edaravone in Delaying Functional Decline in Amyotrophic Lateral Sclerosis: A Meta-Analysis	Disclosure: Dr. Bagnas has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	025	Analysis of Hepatic and Hypothyroidism-related Events in Clinical Trials of Adjunctive Eslicarbazepine Acetate in Children (Aged 4–17 years) with Focal Seizures	Disclosure: Dr. Wheless has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Lundbeck, Mallinckrodt, LivaNova, Eisai, Supernus, GW Pharma, NeuroPace, UCB, Actua, and Aquestive. Dr. Wheless has received research support from NIH, Shainberg Foundation, Mallinckrodt, LivaNova, Eisai, GW Pharma, INSYS Inc, Neuralis, Zogenix, NeuroPace, UCB, Actua, and Aquestive.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	025	NeMeRe, a Multi-Institutional Retrospective and Prospective Registry of Neoplastic Meningitis in Adults	Disclosure: Dr. Ghatnekar has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	025	Monitoring Safety and Effectiveness of Deep Brain Stimulation Systems in a Real-World Population: The Product Surveillance Registry	Disclosure: Dr. Pagan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Sunovion, Teva, Acadia, Adamas, AbbVie, Medtronic, US Word Meds, Merz.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	026	Perceptions of Treatment, Care After Hospital Discharge, and Recovery Following Autoimmune and Infectious Encephalitis	Disclosure: Dr. Nyamu has nothing to disclose.
Headache Clinical Trials I
Start Time	Pub.	Title	Presenter
11:30 AM	026	The Impact of Fremanezumab on Medication Overuse in Patients With Chronic Migraine	Disclosure: Dr. Silberstein has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Stephen D. Silberstein, MD, is a consultant and/or advisory panel member for and has received honoraria from Alder Biopharmaceuticals, Allergan, Amgen, Avanir, eNeura, ElectroCore Medical, Labrys Biologics, Medscape, Medtronic, Neuralieve, NINDS, Pfizer, and Teva.. Dr. Silberstein has received research support from His employer receives research support from Allergan, Amgen, Cumberland Pharmaceuticals, ElectroCore Medical, Labrys Biologics, Eli Lilly, Merz, and Troy Healthcare..
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	026	Wet, Wacky, and Wobbly Without Hydrocephalus	Disclosure: Dr. Hung has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	026	Did Evolution of Evidence Based Stroke Thrombectomy Treatment Change Efficiency Across Stroke Systems of Care?	Disclosure: Dr. Kulhari has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	026	Pitfalls in the Diagnosis of Amyotrophic Lateral Sclerosis in a Hispanic Cohort	Disclosure: Dr. Trikamji has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	026	Selective T-type Calcium Channel Modulator CX-8998 Fully Suppresses Seizures in the GAERS Genetic Model of Epilepsy at Human Achievable Concentrations	Disclosure: Dr. Lee has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Cavion Inc., Karyopharm Therapeutics, and Evelo Biosciences.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	026	Neurological Complications in an ALS Patient with Metastatic Melanoma after Immunotherapy	Disclosure: Dr. Jaffer has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	026	Two Year Outcomes: A Prospective, Double Blinded, Multicenter Randomized Controlled Trial Evaluating Deep Brain Stimulation with a New Multiple Source, Constant Current Rechargeable System in Parkinson's Disease (INTREPID)	Disclosure: Dr. Vitek has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, Abbott, Medtronic. Dr. Vitek has received research support from Boston Scientific, Abbott, Medtronic.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	026	A Common Data Language for Clinical Research Studies: Overview and Update on the National Institute of Neurological Disorders and Stroke (NINDS) Common Data Element (CDE) Recommendations	Disclosure: Dr. Sheikh has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	027	The Contribution of Cognitive Impairment to Perceived Motor Disability in Amyotrophic Lateral Sclerosis	Disclosure: Dr. Ahmadi Jazi has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	027	Adult acute hemorrhagic leukoencephalitis: role of susceptibility-weighted imaging in diagnosis and importance of aggressive early immunotherapy.	Disclosure: Dr. Sugar has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	027	Evidence Improves Outcomes Beyond ‘Belief’: Comparison of Patient Outcomes in Pre- and Post- DAWN era.	Disclosure: Dr. Kulhari has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	027	Clinical and Electrophysiological Profile and Study of Plasma Levels of Neurotoxic Metals in Amyotrophic Lateral Sclerosis	Disclosure: Dr. Garuda has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	027	Cosyntropin is poorly effective in treatment of infantile spasms	Disclosure: Dr. Arya has nothing to disclose.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	027	Eye Movement Abnormalities in CNS Germ Cell Tumors	Disclosure: Dr. Sarangi has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	027	The STN Sweet Spot for Tremor Control in Parkinson’s Disease.	Disclosure: Dr. Stiep has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	027	Evaluation of microRNAs in patients with sporadic amyotrophic lateral sclerosis by liquid biopsy as a disease biomarker	Disclosure: Dr. Takahashi has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	028	Identifying Neural Activity Related to Both How and Why Movements are Performed	Disclosure: Dr. Mazurek has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	028	Rheumatoid Meningitis with Elevated Cyclic Citrullinated Peptide Antibodies and No Evidence of Arthritic Disease	Disclosure: Dr. Rose has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	028	Impact of Race on Mechanical Thrombectomy Safety Outcomes	Disclosure: Dr. Liaw has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	028	Lifetime Sport Practice and Brain Metabolism in Amyotrophic Lateral Sclerosis: a 18F-FDG-PET study	Disclosure: Dr. Moglia has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	028	A 12-month, open-label, repeat-dose safety study of Valtoco ™ (NRL-1, diazepam nasal spray) in patients with epilepsy: Interim report	Disclosure: Yes: all funds paid to Thomas Jefferson University with research support from Medtronic, SK Life Science, Takeda, UCB Pharma, Neurelis, Eisai, Engage, Cavion
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	028	Standardized Intrathecal (IT) Treatment and Surveillance in Leptomeningeal Carcinomatosis (LMC) Improves Patient Outcomes: developing Ommaya IT chemotherapy clinics	Disclosure: Dr. Leese has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	028	Characteristics of oscillatory activity in the globus pallidus internus in patients with Parkinson’s disease	Disclosure: Dr. Zhuang has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	028	Molecular background of ALS based on whole exome sequencing analysis	Disclosure: Dr. Hama has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	029	Polyphenolic compounds ameliorate stress–induced depression by preventing NLRP3 inflammasome priming	Disclosure: Dr. Frolinger has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	029	Progressive Multifocal Leukoencephalopathy in a Patient with Relapsed Multiple Myeloma: A Case Report and Literature Review	Disclosure: Dr. Woodson has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	029	Patterns and Outcomes of Endovascular Therapy in Mild Stroke: A Florida-Puerto Rico Collaboration	Disclosure: Dr. Asdaghi has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	029	Case Report: Familial Amyotrophic Lateral Sclerosis SOD1 c.122A>G (p.Glu41Gly) Mutation with Slow Disease Progression	Disclosure: Dr. Nguyen has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	029	Pharmacokinetic (PK) Assessment of Perampanel Intravenous (IV) Formulation as a Bioequivalent Alternative to Oral Tablet Administration	Disclosure: LR is an employee of Eisai Inc.
Clinical Advances in CNS Cancer Care
Start Time	Pub.	Title	Presenter
11:30 AM	029	Treatment of Cerebral Cysts with Ommaya Reservoir – A Review of 4 Cases	Disclosure: Dr. Mayers has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	029	Longitudinal outcomes of LRRK2 gene mutation parkinsonism undergoing either Subthalamic Nucleus (STN) or Globus Pallidus Internus (GPi) Deep-Brain stimulation (DBS): a multi-group comparison	Disclosure: Dr. Leaver has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	029	Expanding the NeuroChip: A low-cost and efficient diagnostic tool to detect neurological disease-related mutations	Disclosure: Dr. Patankar has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	030	Scopolamine Enhances Low Frequency Cortical Rhythms and Impairs Temporal Processing in the Medial Prefrontal Cortex during an Interval Timing Task	Disclosure: Dr. Zhang has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	030	Systemic Autoimmune Diseases and Idiopathic Epilepsy	Disclosure: Dr. Groshans has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	030	Mechanical Thrombectomy in patients with low NIHSS: A retrospective chart review	Disclosure: Dr. Katyal has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	030	ALS/FTD-linked UBQLN2-P497H Increases K63-linked Polyubiquitinated Protein Levels	Disclosure: Dr. Esengul has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	030	Population Pharmacokinetics Of Lamotrigine In Adults Patients With Epilepsy.	Disclosure: Dr. Chavez has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	030	A kinome-wide RNAi screen identifies ERK2 as a druggable regulator of Shank3 stability	Disclosure: Dr. Holder has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	030	DIRECT-DBS: A Prospective, Multi-center Clinical Study of a Directional DBS Lead – Therapeutic Windows with Directional Stimulation	Disclosure: Dr. Steigerwald has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific, Medtronic, and St. Jude Medical.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	030	Validation of an Axonal Injury Model by Scanning Electron Microscopy Imaging	Disclosure: Dr. Wilson has nothing to disclose.
Behavioral and Cognitive Neurology: Other
Start Time	Pub.	Title	Presenter
11:30 AM	031	Opioid Withdrawal Shifts Amygdalar Transcriptome and is Correlated with Gut Dysbiosis	Disclosure: Dr. O'Sullivan has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	031	A Case of CNS Vasculitic Changes in DRESS Syndrome	Disclosure: Dr. Cagniart has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	031	Experience with Endovascular Therapy in Acute Ischemic Stroke Patients Presenting with Low National Institute of Health Stroke Scale Scores	Disclosure: Dr. Osteraas has nothing to disclose.
Amyotrophic Lateral Sclerosis
Start Time	Pub.	Title	Presenter
11:30 AM	031	The Posttranscriptional Regulation of Ubiquilin2 by HuR in ALS Pathogenesis	Disclosure: Dr. Lu has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	031	Clobazam Retention Rate in Pediatric Epilepsy	Disclosure: Dr. Gonzalez-Giraldo has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	031	Classification of Mutations in TUBB4A: A New Spectrum of Disease	Disclosure: Dr. Charsar has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	031	Deep Brain stimulation in Parkinson: Use of kinematics to study impact of DBS on gait	Disclosure: Dr. Tripathi has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	031	Decreased PI3,5P2 and PI5P in Fibroblasts from Patients with FIG4 Deficiency	Disclosure: Dr. Shisheva has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	032	Brain mass dilemma- Rare presentation of ANCA negative Granulomatosis with polyangiitis	Disclosure: Dr. Ramirez-Salazar has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	032	Less benefits of Mechanical Thrombectomy on Acute Large Vessel Occlusion Stroke Patients Who were Transferred to a Comprehensive Stroke Center	Disclosure: Dr. Elnazeir has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	032	An improved methodology for eliciting the somatosensory evoked potential of the Saphenous Nerve during the intraoperative monitoring in spine surgery	Disclosure: Dr. Sanchez-Roldan has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	032	Time to Onset of Efficacy in Seizure Reduction With Cenobamate (YKP3089) in Patients With Uncontrolled Partial Seizures From 2 Randomized Clinical Trials	Disclosure: Dr. Kamin has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Life Science, Inc.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	032	Spherical Nucleic Acids Show Increased Distribution and Longer Persistence than Linear Oligonucleotides in Rat Brain Following Intrathecal Administration	Disclosure: Dr. Kandimalla has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Exicure, Inc..
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	032	Effects of STN-DBS on axial and non-motor symptoms in patients with Parkinson’s disease: a prospective study	Disclosure: Dr. Miguel has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	032	Neurofilament Light Chain (NfL) Levels in CSF, Serum, and Plasma of Healthy Donors Using the Quanterix NfL Advantage Kit™	Disclosure: Dr. Harp has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	033	BDNF as a surrogate biomarker for systemic chronic damage in lupus.	Disclosure: Dr. Alessi has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	033	Predictors of Poor Outcome after Mechanical Thrombectomy with Successful Recanalization	Disclosure: Dr. Anadani has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	033	Carpal Tunnel Syndrome in Children from a Pediatric Neuromuscular Center	Disclosure: Dr. Irumudomon has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	033	Effects of Cenobamate on GABA-A Receptor Modulation	Disclosure: Dr. Sharma has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	033	Phenotypic Characterization of Individuals with SYNGAP1 Pathogenic Variants Reveals Correlation Between Posterior Dominant Rhythm and Developmental Progression	Disclosure: Dr. Jimenez Gomez has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	033	Long-term Effects of Bilateral Subthalamic Deep Brain Stimulation on Postural Instability and Gait Disturbance in Parkinson's Disease	Disclosure: Dr. Shin has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	033	The Isoniazid Metabolites Pyridoxal Isonicotinoyl Hydrazone and Hydrazine Regulate Heme Biosynthesis	Disclosure: Dr. Brewer has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	034	Infliximab-induced Demyelinating Polyneuropathy in Neurosarcoidosis	Disclosure: Dr. Lineback has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	034	Hemorrhagic transformation after Mechanical Thrombectomy Revascularization in Large Vessel Occlusion Ischemic Stroke	Disclosure: Dr. Saini has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	034	Kinetics And Fiber Distribution Of The Three Muscle Heads Of Triceps For a Better C7 Myotomal EMG Study	Disclosure: Dr. Noto has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	034	The Pharmacokinetics of Cenobamate in Special Populations	Disclosure: Dr. Greene has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SK Life Science, Inc..
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	034	Establishing Clinical Trial Readiness of the Rett Syndrome Hand Function Measure	Disclosure: Dr. Leonard has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	034	Early Experiences with Multiple Independent Current Control DBS in Parkinson’s Disease	Disclosure: Dr. Lorido has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	034	Evaluation of apolipoprotein E and a-synuclein as potential biomarkers in CSF to monitor pharmaco-therapeutic efficacy in dopamine dictated disease states of Parkinson's disease and schizophrenia	Disclosure: Dr. HARIPRASAD has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	035	Movement Disorders associated with Systemic Autoimmunity: A Case Series	Disclosure: Dr. McDonald has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	035	Diabetes Mellitus Predicts Symptomatic Intracerebral Hemorrhage Following Thrombectomy in Acute Ischemic Stroke	Disclosure: Dr. Montalvo Perero has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	035	Continuous Vagus Nerve Monitoring using the Laryngeal Adductor Reflex	Disclosure: Dr. Sanchez-Roldan has nothing to disclose.
Epilepsy: Antiseizure Medications I
Start Time	Pub.	Title	Presenter
11:30 AM	035	Efficacy and Tolerability of Clobazam in Adult Drug-Refractory Epilepsy	Disclosure: Dr. Levinson has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	035	Resting-State EEG Abnormalities in Children with Rett Syndrome	Disclosure: Dr. Tomlinson has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	035	Men Are More Likely to Have DBS for Tremor in Parkinson's Disease	Disclosure: Dr. Dalrymple has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	035	Understand the disease emergence in hereditary transthyretin amyloidosis (hATTR): a longitudinal study of asymptomatic carriers to inaugural disease manifestations.	Disclosure: Dr. Plante-Bordeneuve has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	036	Skin, Gut and Nervous system – Think Degos Disease	Disclosure: Dr. Goswami has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	036	Higher Baseline LDL levels and Increased Hemorrhagic Risk in Ischemic Stroke Patients Undergoing Mechanical Thrombectomy	Disclosure: Dr. Roman Casul has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	036	Utility of Bumps Test in The Diagnosis of Carpal Tunnel Syndrome Compared to Nerve Conduction Study	Disclosure: Dr. Ghasemi has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	036	JASPER Early Intervention in TSC (JETS): Methods to enhance study participation and scalability in rare disorders	Disclosure: Dr. Jeste has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche Pharmaceuticals.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	036	Refractory Gait Freezing Following GPi Stimulation for Parkinson's Disease	Disclosure: Dr. Sketchler has nothing to disclose.
General Neurology: Research Advances in Diagnosis, Pathogenesis, and Biomarkers
Start Time	Pub.	Title	Presenter
11:30 AM	036	Association between LDL-C/HDL-C ratio and Hemorrhagic Transformation in Acute Ischemic Stroke Patients	Disclosure: Dr. Wang has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	037	Post-Malaria Neurological Syndrome	Disclosure: Dr. Waseem has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	037	Improved Outcomes after Mechanical Thrombectomy for In-hospital Strokes	Disclosure: Dr. Ehab has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	037	Hematoma Risk After Needle Electromyography (EMG) In Patients on Newer Anticoagulants	Disclosure: Dr. Nagarajan has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	037	Recurrent mosaic MTOR c.5930C>T (p.Thr1977Ile) Variant Causing Megalencephaly, Asymmetric Polymicrogyria, and Cutaneous Pigmentary Mosaicism	Disclosure: Dr. Handoko has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	037	Dorsal GPi/GPe DBS Induced Dyskinesia	Disclosure: Dr. El Kouzi has nothing to disclose.
General Neurology: Rare and Unusual Presentations of Neurologic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	037	Oromandibular dystonia in a patient with herpes simplex virus encephalitis (HSVE)	Disclosure: Dr. Josephy has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	038	Acute Disseminated Encephalomyelitis In An Adult Associated With Staphylococcus Aureus Bacteremia And Infective Endocarditis	Disclosure: Dr. Shujaat has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	038	A Comparison of Outcomes Associated With Mechanical Thrombectomy in Acute Ischemic Stroke Patients Performed Within and Outside Clinical Trials In The United States	Disclosure: Dr. Qureshi has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	038	Ratio of Distal to Proximal Epidermal Nerve Fiber Density as Predictor of Small Fiber Neuropathy	Disclosure: Dr. Farrenburg has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	038	Iron deficiency and response to treatment with regard to sleep difficulties in Angelman Syndrome	Disclosure: Dr. Ryan has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	038	Outcomes of Deep Brain Stimulation Surgery in Parkinson's Disease: Real Life Experience from a Tertiary Care Center	Disclosure: Dr. Brennan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbvie.
General Neurology: Rare and Unusual Presentations of Neurologic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	038	Plateau waves of intracranial pressure mimicking seizure in a patient with fungal meningitis	Disclosure: Dr. Wu has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	039	Optic Neuritis and Spinal Nerve Root Masses- An Unusual Presentation of Neurosarcoidosis	Disclosure: Dr. Zafar has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	039	The Impact of “July Phenomenon” on Door-to-Groin Time and Long-term ?Outcome of Stroke Patients Treated with Mechanical Thrombectomy	Disclosure: Dr. Almallouhi has nothing to disclose.
Neurophysiology in Neuromuscular Disorders I
Start Time	Pub.	Title	Presenter
11:30 AM	039	Neuromuscular ultrasound for the non-invasive assessment of breast cancer patients with peripheral neuropathy from taxanes	Disclosure: Dr. Strowd has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Innocrin Pharmaceuticals, Monteris Medical, and Novocure. Dr. Strowd has received personal compensation in an editorial capacity for Neurology. Dr. Strowd has received research support from American Society of Clinical Oncology Conquer Cancer Foundation, Southeastern Brain Tumor Foundation, and Jazz Pharmaceuticals.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	039	A Expanded Cohort Study of the X-linked HNRNPH2-related Neurodevelopmental Disorder	Disclosure: Dr. Bain has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	039	Outcomes of a Prospective, Multicenter, International Registry of Deep Brain Stimulation for Parkinson's Disease	Disclosure: Dr. Deuschl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Boston Scientific. Dr. Deuschl has received personal compensation in an editorial capacity for European Academy of Neurology. Dr. Deuschl has received royalty, license fees, or contractual rights payments from Thieme publisher and has received research support from Medtronic and Boston Scientific.
General Neurology: Rare and Unusual Presentations of Neurologic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	039	Case Report of Transient Acute Parkinsonism in the setting of West Nile Virus Encephalitis	Disclosure: Dr. Vanguru has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	040	An adolescent female with angiography-negative childhood primary angiitis of the central nervous system	Disclosure: Dr. Leung has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	040	Mechanical Thrombectomy In Acute Ischemic Stroke: Etiology And Trends Of Readmissions In A National Population-based Cohort Study (2010-2014)	Disclosure: Dr. Li has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	040	Case Series: Expansion of MT-ATP6 Pathogenic Variant Phenotype	Disclosure: Dr. Purohit has nothing to disclose.
Parkinson's Disease Surgical, Stem Cell and Gene Therapies
Start Time	Pub.	Title	Presenter
11:30 AM	040	Tradeoffs in current steering technologies for deep brain stimulation	Disclosure: Dr. Zhang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Abbott. Dr. Zhang has received research support from Abbott.
General Neurology: Rare and Unusual Presentations of Neurologic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	040	A Rare Case of Peripheral Neurolymphomatosis in Cutaneous T-cell Lymphoma	Disclosure: Dr. Paul has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	041	Neurologic Involvement in Seronegative Sjögren’s Syndrome with Positive Lip Biopsy: A Single Center Experience	Disclosure: Dr. Wong has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	041	Endovascular Thrombectomy in Acute-Onset Ischemic Stroke – Beyond the Standard Time Windows: A Case Report and a Review of the Literature	Disclosure: Dr. So has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	041	Developmental and behavioral characteristics of children with Dup15q syndrome	Disclosure: Dr. Distefano has nothing to disclose.
Huntington's Disease and Other Choreas
Start Time	Pub.	Title	Presenter
11:30 AM	041	Salivary Biomarkers in Huntington’s Disease	Disclosure: Dr. Corey-Bloom has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Genentech, Teva. Dr. Corey-Bloom has received research support from Vaccinex, Wave Life Sciences, CHDI.
General Neurology: Rare and Unusual Presentations of Neurologic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	041	Neurological symptoms in a patient diagnosed with adrenal oncocytic cortical carcinoma.	Disclosure: Dr. Aguilar Tejedor has nothing to disclose.
Inflammatory Neurological Complications of Systemic Disease
Start Time	Pub.	Title	Presenter
11:30 AM	042	Recurrent Occipital Lobe Ischemic Strokes in COPA Syndrome	Disclosure: Dr. Morgan has nothing to disclose.
Endovascular Therapy in Acute Ischemic Stroke
Start Time	Pub.	Title	Presenter
11:30 AM	042	Role of CT Perfusion Parameters and Collateral Score in Predicting Outcomes in Large Vessel Occlusion Strokes Who Received Both Intravenous Alteplase and Endovascular Thrombectomy	Disclosure: Dr. Das has nothing to disclose.
Child Neurology: Neurogenetics
Start Time	Pub.	Title	Presenter
11:30 AM	042	Children with Neurogenetic Disorders Hospitalized with Community-acquired Pneumonia are at Increased Risk for Poor Outcomes	Disclosure: Dr. Kolikonda has nothing to disclose.
Huntington's Disease and Other Choreas
Start Time	Pub.	Title	Presenter
11:30 AM	042	Preliminary Reliability and Validity of a Novel Digital Biomarker Smartphone Application to Assess Cognitive and Motor Symptoms in Huntington’s Disease (HD)	Disclosure: Dr. Lipsmeier has received personal compensation for consulting, serving on a scientific